Table 6. The regimen following disease progression.
Regimen | n = 41 | (%) |
---|---|---|
Triplet re-induction | 5 | 12 |
Doublet + antibodies | 14 | 34 |
Anti-EGFR ± CPT-11 | 6 | 15 |
Late-line | 11 | 27 |
Best supportive care | 5 | 12 |
Abbreviations: Anti-EGFR, anti-epidermal growth factor receptor antibodies; CPT-11, irinotecan.